Refined Staging Classification of Cardiac Damage Associated with Aortic Stenosis and Outcomes after Transcatheter Aortic Valve Implantation

Okuno, Taishi; Heg, Dik; Lanz, Jonas; Praz, Fabien Daniel; Brugger, Nicolas; Stortecky, Stefan; Windecker, Stephan; Pilgrim, Thomas (2021). Refined Staging Classification of Cardiac Damage Associated with Aortic Stenosis and Outcomes after Transcatheter Aortic Valve Implantation (In Press). European Heart Journal - Quality of Care and Clinical Outcomes Oxford University Press (OUP): Policy B - Oxford Open Option B 10.1093/ehjqcco/qcab041

[img] Text
Okuno_EurHeartJQualCareClinOutcomes_2021_AAM.pdf - Accepted Version
Restricted to registered users only until 5 June 2022.
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy
[img] Text
Okuno_EurHeartJQualCareClinOutcomes_2021_supplmat.pdf - Supplemental Material
Restricted to registered users only until 5 June 2022.
Available under License Publisher holds Copyright.

Download (343kB) | Request a copy

Aims

A new staging classification of aortic stenosis (AS) characterizing the extent of cardiac damage was established and validated in patients undergoing transcatheter aortic valve implantation (TAVI). We aimed to validate an updated classification system in patients undergoing TAVI.

Methods and Results

In a prospective TAVI registry, AS patients were categorized into the following stages: no cardiac damage (Stage 0), left ventricular damage (Stage 1), left atrial or mitral valve damage (Stage 2), pulmonary vasculature or tricuspid valve damage (Stage 3), or right ventricular (RV) damage or low-flow state (Stage 4). Stage 3 was sub-divided into Stage 3a (≤moderate pulmonary hypertension) and Stage 3b (severe pulmonary hypertension). Stage 4 was sub-divided into Stage 4a (low-flow without RV dysfunction), Stage 4b (RV dysfunction without low-flow), and Stage 4c (RV dysfunction with low-flow). The primary endpoint was all-cause death at 1 year. Among 1,156 eligible patients, 14 were classified as Stage 0, 38 as Stage 1, 105 as Stage 2, 278 as Stage 3, and 721 as Stage 4. There was a stepwise increase in mortality according to advancing stages of cardiac damage: 3.9% (Stage 0-1), 9.6% (Stage 2), 14.1% (Stage 3), and 17.4% (Stage 4) (p = 0.002). After multivariable adjustment, only Stage 3b, Stage 4b, and Stage 4c conferred a significantly increased risk of mortality compared to Stage 0-1.

Conclusion

More than one third of patients had advanced cardiac damage (severe pulmonary hypertension or RV dysfunction) before TAVI, associating with a 5- to 7-fold increased risk of mortality at 1 year.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology
04 Faculty of Medicine > Pre-clinic Human Medicine > CTU Bern

UniBE Contributor:

Okuno, Taishi; Heg, Dierik Hans; Lanz, Jonas; Praz, Fabien Daniel; Brugger, Nicolas Jacques; Stortecky, Stefan; Windecker, Stephan and Pilgrim, Thomas

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2058-5225

Publisher:

Oxford University Press (OUP): Policy B - Oxford Open Option B

Language:

English

Submitter:

Doris Kopp Heim

Date Deposited:

08 Jun 2021 21:48

Last Modified:

10 Jun 2021 18:29

Publisher DOI:

10.1093/ehjqcco/qcab041

PubMed ID:

34086888

BORIS DOI:

10.48350/156783

URI:

https://boris.unibe.ch/id/eprint/156783

Actions (login required)

Edit item Edit item
Provide Feedback